NCT05846737View on ClinicalTrials.gov

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2028

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

anti-BCMA CAR-T

Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA CAR+T cells/kg.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER